Stock Update: Corinthian Colleges Inc (NASDAQ:COCO); TransAtlantic Petroleum Ltd. (NYSEMKT:TAT); Bristol-Myers Squibb Company (NYSE:BMY)
Dallas, Texas, 09/29/2014 (ustrademedia) – Corinthian Colleges Inc (NASDAQ:COCO) disclosed on 27th September that it had entered into a Consent Agreement with its main lender Bank of America Corp (NYSE:BAC) on September 25, 2014. The consent agreement was arrived at with respect to the Credit Facility which the ‘for profit’ educational provider had negotiated with the lenders on May 17, 2012. The restated agreement also covers the responsibilities of Everest Colleges Canada, Inc that is the guarantor for this credit deal. The restructuring of the original deal was necessitated after the U.S. Department of Education threatened to stop “Title IV disbursements” to the firm. If in case the lenders did not approve the “Second Amendment” entered into between DOE and the company.
Oil and gas firm, TransAtlantic Petroleum Ltd. (NYSEMKT:TAT) announced on 26th September that it had successfully completed the due diligence process with respect to finances and operations of Stream Oil & Gas Ltd. The due diligence was conducted further to its September 3, 2014 announcement to buyout Stream Oil and Gas Ltd. With the successful completion of the due diligence process, the firm hopes to complete the acquisition process by November 2014. The next step in the acquisition process involves the shareholders of the target firm approving the deal on or before November 12, 2014. The oil firm has announced that in order to persuade the shareholders of Stream Oil and Gas Ltd to vote for the deal completion. They would be hosting investor meetings in Canadian cities of “Vancouver, Calgary and Toronto.”
Drug maker Bristol-Myers Squibb Company (NYSE:BMY) announced on September, 26th 2014 that it has set regulatory milestones for its chief drug candidate Opdivo (nivolumab). The milestones include roadmaps to seek approvals from both the U.S and European drug regulators for afore mentioned drug candidate. The drug maker’s press note indicated that the U.S. Food and Drug Administration has green lighted its “Biologics License Application” seeking fast tracking of the review process of the drug.